Business
Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX- 950 Presentations at the Upcoming AASLD Meeting
Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX- 950 Presentations at the Upcoming AASLD Meeting.
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n\n\n\n\nCAMBRIDGE, Mass., Nov. 9 /CNW/ -- Vertex Pharmaceuticals\nIncorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday,\nNovember 11, 2005 at 9:00 a.m. EST. During the call, the Company will review\nresults from the Phase Ib study of its investigational oral hepatitis C\nprotease inhibitor, VX-950, that will be presented while attending the 56th\nAmerican Association for the Study of Liver Diseases (AASLD) Annual Meeting.\nThe meeting is being held in San Francisco, CA from November 11-15, 2005.\nThe webcast will be available to all interested parties through Vertex's\nwebsite, http://www.vrtx.com, and will be archived on the Company's website\nuntil November 25, 2005. To access the webcast, go to the investor center and\nselect 'conference calls.' To ensure a timely connection, it is recommended\nthat users register at least 15 minutes prior to the scheduled webcast.\nVertex is also providing a podcast MP3 file available for download on the\nVertex website, http://www.vrtx.com, until November 25, 2005.\n\nAbout Vertex\nVertex Pharmaceuticals Incorporated is a global biotechnology company\ncommitted to the discovery and development of breakthrough small molecule\ndrugs for serious diseases. The Company's strategy is to commercialize its\nproducts both independently and in collaboration with major pharmaceutical\ncompanies. Vertex's product pipeline is principally focused on viral\ndiseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes\nthe HIV protease inhibitor, Lexiva, with GlaxoSmithKline.\nLexiva is a registered trademark of the GlaxoSmithKline group of\ncompanies.\nVertex's press releases are available at http://www.vrtx.com.\n\n Vertex Contact:\n Lora Pike, Manager, Investor Relations, (617) 444-6755\n\n\n","length":1834,"tagName":"div"}]